Savant Capital LLC Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

Savant Capital LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 10.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 225,753 shares of the company’s stock after selling 25,353 shares during the quarter. Savant Capital LLC’s holdings in Johnson & Johnson were worth $35,161,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Moneta Group Investment Advisors LLC boosted its stake in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Norges Bank bought a new position in shares of Johnson & Johnson in the 4th quarter worth $4,609,399,000. Capital International Investors raised its stake in Johnson & Johnson by 62.7% during the 2nd quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock worth $4,605,627,000 after buying an additional 10,724,110 shares during the period. Journey Strategic Wealth LLC raised its stake in Johnson & Johnson by 161,420.2% during the 2nd quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock worth $1,204,404,000 after buying an additional 7,271,978 shares during the period. Finally, Morgan Stanley raised its stake in shares of Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the period. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Stock Down 0.1 %

Shares of NYSE:JNJ opened at $157.98 on Thursday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The firm has a market capitalization of $380.30 billion, a PE ratio of 11.44, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53. The firm has a fifty day moving average of $158.20 and a 200 day moving average of $159.04. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. Johnson & Johnson’s revenue was down 9.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.35 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.01%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s payout ratio is 34.47%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Morgan Stanley reduced their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 24th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Tuesday. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Finally, Barclays raised their target price on Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 12th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $176.14.

Get Our Latest Research Report on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.